Levosimendan - Long-term inodilation in an infant with myocardial infarction;Säugling mit therapie-refraktärer suprasystemischer pulmonaler hypertonie nach myokardinfarkt: Intermittierende stabilisierung mit levosimendan, einem neuartigen langzeit-inodilatator

Zeitschrift fur Kardiologie

Volumn 93, Issue 3, 2004, Pages 234-239

  Luther, Y C ^a   Schulze Neick, I ^a   Stiller, B ^a   Ewert, P ^a   Redlin, M ^a   Nasseri, B ^a   Muhler E G ^b   Hetzer, R ^a   Lange, P E ^a  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

Author keywords

Left ventricular dysfunction; Levosimendan; Pulmonary hypertension

Indexed keywords

CATECHOLAMINE; LEVOSIMENDAN;

ARTICLE; CORONARY ARTERY OBSTRUCTION; DRUG EFFICACY; DRUG MECHANISM; FEMALE; HEART FUNCTION; HEART INDEX; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HUMAN; INFANT; INFANT DISEASE; INOTROPISM; LEFT CORONARY ARTERY; LONG TERM CARE; LUNG VASCULAR RESISTANCE; MAJOR CLINICAL STUDY; MALE; MITRAL VALVE REGURGITATION; PULMONARY HYPERTENSION; VASODILATATION;

CARDIAC OUTPUT, LOW; CARDIOTONIC AGENTS; CORONARY STENOSIS; CORONARY VESSEL ANOMALIES; ECHOCARDIOGRAPHY, DOPPLER; ELECTROCARDIOGRAPHY, AMBULATORY; HUMANS; HYDRAZONES; HYPERTENSION, PULMONARY; INFANT; INFANT, NEWBORN; LONG-TERM CARE; MALE; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATIONS; PULMONARY ARTERY; PULMONARY WEDGE PRESSURE; PYRIDAZINES; STROKE VOLUME; TREATMENT OUTCOME; VASCULAR RESISTANCE; VASODILATOR AGENTS;

EID: 1642443537     PISSN: 03005860     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00392-004-0053-9     Document Type: Article

References (12)

1. De Witt BJ, Ibrahim IN, Bayer E, Fields AM, Richards TA, Banister RE, Kaye AD (2002) An analysis of responses to Levosimendan in the pulmonary vascular bed of the cat. Anesth Analg 94:1427-1433
2. Endo M, Yamaki S, Ohmi M, Tabayashi K (2000) Pulmonary vascular changes induced by congenital obstruction of pulmonary venous return. Ann Thorac Surg 69:193-197
3. Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L (2002) Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 360:196-202
4. Guertl B, Noehammer C, Hoefler G (2000) Metabolic cardiomyopathies. Int J Exp Pathol 81:349-372
5. Kivikko M, Antila S, Eha J, Lehtonen L, Pentikainen PJ (2002) Pharmacokinetics of levosimendan and its metabolites during and after a 24-hour continuous infusion in patients with severe heart failure. Int J Clin Pharmacol Ther 40:465-471
6. Lehtonen LA (2001) Levosimendan: a parental calcium-sensitising drug with additional vasodilatory properties. Exp Opin Invest Drugs 10:955-970
7. Lilleberg J, Nieminen MS, Akkila J, Heikkilä L, Kuitunen A, Lehtonen L, Verkkala K, Mattila S, Salmenperä M (1998) Effects of a new calcium sensitizer, levosimendan, on haemodynamics, coronary blood flow and myocardial substrate utilization early after coronary artery bypass grafting. Eur Heart J 19:660-668
8. Nieminen MS, Moiseyev VS, Andrejevs N, Lehtonen LA, Laine T, Poder P, Kobalava J, Golikov AP, Lazebnik LB, Ruda MY, Lie KI (1999) Randomized study on safety and effectiveness of levosimendan in patients with left ventricular failure after an myocardial infarct. Circulation (Suppl 1):100I-646
9. Nieminen MS, Akkila J, Hasenfuss G, Kleber FX, Lehtonen L, Mitrovic V, Nyquist O, Remme WJ (2000) Hemodynamic and neurohumoral effects of continuous infusion of levosimendan in patients with congestive heart failure. J Am Coll Cardiol 36:1903-1912
10. Packer M, Nieminen MS, Hasenfuss G, Follath F, Cleland JGF, Moiseyev VS, Lechat P, Pajunen P, Akkila J (1999) Effect of intravenous levosimendan, a calcium sensitizer, on the survival of hospitalized patients with heart failure. Circulation (Suppl 1): 100I-646
11. Pfannschmidt J, Ruskowski H, de Vivie ER (1992) Bland-White-Garland syndrome. Clinical aspects, diagnosis, therapy. Klin Padiatr 204:328-334
12. Turanlahti M, Antila S, Rantanen S, Lehtonen L (1999) Pharmacokinetics and safety profile of Levosimendan in pediatric patients evaluated for cardiac surgery. Intensive Care Med 25:72